Auris Medical: Surges as nasal spray to prevent COVID-19 shows promise

Altamira Therapeutics

01/12/2020 16:26

** U.S.-listed shares of Switzerland-based biotechnology co
 EARS.O  more than double to $3.45 - set for a near two-year
high
    ** Stock is biggest pct gainer across U.S. exchanges 
    ** Co says daily treatment with its experimental drug-free
nasal spray, AM-301, showed effective protection against the
SARS-CoV-2 viral infection in in-vitro study  urn:newsml:reuters.com:*:nGNX2SBkjJ
    ** AM-301 was tested for its capability to prevent or
mitigate infection of nasal epithelial cells, which are the
first barrier against inhaled pathogens and allergens
    ** Co plans to submit regulatory applications for AM-301 in
2021
    ** Up to Monday's close, stock down 31.5% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))